Externí hodnocení kvality (SEKK, DAkkS, PREVECAL, SZÚ, INSTAND)

SEKK

CÍL

AIM 1/16   Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 2/16 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 1/17 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 2/17 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 1/18 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 2/18 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 1/19 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 2/19 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 1/20  Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 2/20 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 1/21 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 2/21 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 2/21-923 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 1/22 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 1/22-923 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

AIM 2/22 Autoimunita (ANA, ANCA, Anti-MPO, Anti-PR3, Anti-ENA, ACA, Anti-ds-DNA, Anti-NUKL IgG)

APLA

APLA 1/16 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 3/16  Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 1/17  Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 2/17 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 1/18 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 2/18 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 1/19 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 2/19 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 1/20 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 2/20 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 1/21 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 2/21 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 1/22 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

APLA 2/22 Antifosfolipidové aktivity (Anti-kardiolipin IgG, IgM; Anti-beta2-GP 1 IgG, IgM)

IGIT

IGIT 1/16 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA)

IGIT 2/16 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA)

IGIT 1/17 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA)

IGIT 2/17  Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA)

IGIT 1/18 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA)

IGIT 2/18 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA)

IGIT 1/19 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA)

IGIT 2/19 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA)

IGIT 1/20 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA

IGIT 2/20 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA

IGIT 1/21 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA

IGIT 2/21 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA

IGIT 1/22 Imunopatologie GIT (Anti-gliadin (deamidový) IgG, IgA; Anti-endomyzium IgA; Anti-transglutamináza IgA

RF

RF 1/16  Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 2/16 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 1/17 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 2/17 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 1/18 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 2/18 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 1/19 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 2/19 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 1/20 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 2/20 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 1/21 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 2/21 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 1/22 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

RF 2/22 Diagnostika revmatoidní artritidy a ASLO (RF screening, IgG, IgA, IgM; Anti-CCP IgG; Anti-MCV)

PRASE

PIG/19 Podtřídy IgG (IgG 4)

PIG/20 Podtřídy IgG (IgG 4)

IFT

IFT 1/16  Imunofenotypizace

IFT 2/2016  Imunofenotypizace

IFT 1/2017  Imunofenotypizace

IFT 2/2017  Imunofenotypizace

IFT 1/2018  Imunofenotypizace

IFT 2/2018  Imunofenotypizace

IFT 1/2019  Imunofenotypizace

IFT 2/2019 Imunofenotypizace

IFT 1/2020 Imunofenotypizace

IFT 2/2020  Imunofenotypizace

IFT 1/2021 Imunofenotypizace

IFT 2/2021 Imunofenotypizace

IFT 2/2022 Imunofenotypizace

T

T 1/22 Protilátky proti SARS-CoV-2 (studie)

 



DAkkS

Hodnocení kvality DAkkS EuroImmun

QV1510-140325 Protilátky proti buněčným jádrům, Anti-dsDNA, Anti-nukleozomy, LIA

QV2132-140325   Anti- borrelia

QV1505-140513 Anti-CCP

QV1632-140513 anti-kardiolipin, anti-β2 glykoprotein

QV1913-140513-1 Anti-tTG, Anti-Endomysium, Anti-Gliadin

QV1913-140513-2  Anti-Gliadin

QV1200-140513-1 Protilátky proti granulocytům

QV1200-140513-2 Anti-MPO, Anti-PR3

QV2790-140325 Protilátky proti viru Epstein-Barrové

Hodnocení kvality DAkkS EuroImmun Lübeck

QV1510-220315 Ana 1/2022

QV2132-220315 Borrelia 1/2022

QV2606-220315 SARS-CoV-2 1/2022 

QV1530-220315 Myopathies 1/2022

QV2580-220315 Parvovirus 1/2022





SZÚ - Státní zdravotní ústav